Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR

Orchid Pharma receives DCGI approval for combination of Cefepime and Enmetazobactam

DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable

A.forall expands US generics portfolio

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach

UK journal publishes complex case of severe pan-drug resistant infection in US liver transplant patient successfully treated with Zaynich

This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions

Orchid Pharma Q2 FY25 PAT up 26% YoY driven by strategic initiatives for market expansion

Successful use of Zidebactam/Cefepime to treat skull bone infection & pneumonia caused by extreme-drug resistant pseudomonas

With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained

Orchid Pharma's 'Exblifep' receives USFDA approval

Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA

Orchid Pharma's Exblifeb granted EMA approval

Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia